Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
Medtronic’s newest closed-loop system posts decent pivotal data, but Insulet and Abbott are waiting in the wings.
For diabetes devices interoperability is key, and partnerships between Insulet, Dexcom and Abbott show that rival groups see the benefits of working together.
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Forming partnerships with a number of players in diabetes technology is the key to growth, according to Ascensia Diabetes Care.
Dexcom can capitalise on its new algorithm technology, but is now enmeshed in a tangled web of partnerships.
Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.